Type 2 Diabetes – Unmet Need – Detailed, Expanded Analysis: Injectables (US/EU)
The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Notable market growth is expected from the sodium glucose cotransporter-2 (SGLT-2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists due to their efficacy in glycemic control and weight loss and demonstration of cardiovascular (CV) benefits, although they will face reimbursement hurdles and an increasingly stringent regulatory environment. Consequently, a high unmet need exists for affordable drugs that can safely and effectively control T2D in the long term.
QUESTIONS ANSWERED
- How do endocrinologists rate current T2D drug classes such as the DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists as well as long-acting, short-acting, and rapid-acting insulins?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and prices are needed from new antidiabetic drugs in order to be preferred by endocrinologists?
- Is an injectable drug with CV benefits preferable to an oral drug offering stronger glycemic control? Discover the answer with DRG’s fully customizable Target Product Profile (TPP) simulator.
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 30 European endocrinologists fielded in August 2019.
Key companies: Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma, Boehringer Ingelheim.
Key drug classes: DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists (once daily), GLP-1 receptor agonists (once weekly), long-acting insulins, short-acting insulins, rapid-acting insulins.
Table of contents
- Type 2 Diabetes - Unmet Need - Detailed, Expanded Analysis: Injectables (US/EU)
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Efficacy
- Safety and Tolerability
- Convenience of Administration
- Nonclinical Factors
- Rationale for Drug Selection
- Products for Type 2 Diabetes
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Endocrinologists' Prescribing Decisions in Type 2 Diabetes
- Importance of Efficacy Attributes to Prescribing Decisions in Type 2 Diabetes: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Type 2 Diabetes: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Type 2 Diabetes: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Type 2 Diabetes: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Type 2 Diabetes: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Type 2 Diabetes: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Type 2 Diabetes: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Type 2 Diabetes: United States
- Overall Performance of Key Therapies for Type 2 Diabetes: Europe
- Mean Overall Performance of Key Therapies for Type 2 Diabetes: United States and Europe
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Type 2 Diabetes Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Type 2 Diabetes
- Surveyed Endocrinologistsu2019 Satisfaction with the Performance of Key Therapies for Type 2 Diabetes on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Endocrinologistsu2019 Satisfaction with the Performance of Key Therapies for Type 2 Diabetes on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Type 2 Diabetes: United States
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Type 2 Diabetes: Europe
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Type 2 Diabetes: United States
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Type 2 Diabetes: Europe
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Type 2 Diabetes: United States
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Type 2 Diabetes: Europe
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Type 2 Diabetes: United States
- Surveyed Endocrinologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Type 2 Diabetes: Europe
- Key Findings: Unmet Need in Type 2 Diabetes and Related Indications
- Surveyed Endocrinologists' Ascribed Level of Unmet Need in Type 2 Diabetes and Related Indications: United States
- Surveyed Endocrinologists' Ascribed Level of Unmet Need in Type 2 Diabetes and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Type 2 Diabetes Market and Emerging Therapy Insights
- Opportunity: An Agent with Benefits in a Wider Range of Cardiovascular Diseases
- Opportunity: An Agent with Improved Renal Benefits
- Opportunity: An Agent with Weight-Loss Efficacy
- Areas of Opportunity in the Type 2 Diabetes Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- Type 2 Diabetes Target Product Profile: Attribute Importance
- Mean Reduction in HbA1c Levels from Baseline After One Year
- Change in Body Weight After One Year
- Reduction in Major Adverse Cardiovascular Event (MACE) Rates Versus Placebo
- Reduction in Risk of Progression to End-Stage Renal Disease (ESRD) Versus Placebo
- Risk of Serious Adverse Events
- Route of Administration
- Price per Day
- Conjoint Analysis-Based Simulations of Market Scenarios
- Type 2 Diabetes Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
- Type 2 Diabetes Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
- Type 2 Diabetes Market Simulations: Target Product Profiles Included in Scenario 1
- Type 2 Diabetes Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
- Type 2 Diabetes Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
- Type 2 Diabetes Market Simulations: Target Product Profiles Included in Scenario 2
- Type 2 Diabetes Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 3
- Type 2 Diabetes Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 3
- Type 2 Diabetes Market Simulations: Target Product Profiles Included in Scenario 3
- Appendix
- Key Abbreviations
- Bibliography
- Introduction
Rameshwar Prajapati, M.S.(Pharm.), Ph.D., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He focuses on the treatment of obesity and peripheral arterial disease but has also authored content on other cardiovascular, renal, and metabolic indications. Dr. Prajapati earned a bachelor’s degree in pharmacy from Hari Singh Gour University and a master’s degree and Ph.D. in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, S.A.S. Nagar India.